Regeneron Pharmaceuticals Inc. (REGN)

345.33
NASDAQ : Health Technology
Prev Close 341.65
Day Low/High 338.57 / 347.33
52 Wk Low/High 281.89 / 416.49
Avg Volume 687.40K
Exchange NASDAQ
Shares Outstanding 106.32M
Market Cap 36.98B
EPS 11.30
P/E Ratio 21.84
Div & Yield N.A. (N.A)

Latest News

ODYSSEY OUTCOMES Investigators Highlight At AHA That Praluent® (alirocumab) Injection Was Associated With Fewer Deaths From Any Cause

ODYSSEY OUTCOMES Investigators Highlight At AHA That Praluent® (alirocumab) Injection Was Associated With Fewer Deaths From Any Cause

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

Notable Friday Option Activity: REGN, OMER, PBPB

Notable Friday Option Activity: REGN, OMER, PBPB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Regeneron Pharmaceuticals, Inc. , where a total of 5,281 contracts have traded so far, representing approximately 528,100 underlying shares.

New England Journal Of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial

New England Journal Of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)

Regeneron Pharmaceuticals Becomes #19 Most Shorted Nasdaq 100 Component, Replacing PACCAR

Regeneron Pharmaceuticals Becomes #19 Most Shorted Nasdaq 100 Component, Replacing PACCAR

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.

FDA Approves Asthma Indication For Dupixent&reg; (dupilumab)

FDA Approves Asthma Indication For Dupixent® (dupilumab)

Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

FDA Approves Asthma Indication For Dupixent&reg; (dupilumab)

FDA Approves Asthma Indication For Dupixent® (dupilumab)

TARRYTOWN, N.Y.

FDA Approves Asthsma Indication For Dupixent&reg; (dupilumab)

FDA Approves Asthsma Indication For Dupixent® (dupilumab)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

Kevzara&reg; (sarilumab) Data At The 2018 ACR/ARHP Annual Meeting Provide Additional Insight On Safety And Efficacy In Rheumatoid Arthritis

Kevzara® (sarilumab) Data At The 2018 ACR/ARHP Annual Meeting Provide Additional Insight On Safety And Efficacy In Rheumatoid Arthritis

Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response

Dupixent&reg; (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

Dupixent® (dupilumab) Showed Positive Topline Results In Two Phase 3 Trials Of Patients With Chronic Rhinosinusitis With Nasal Polyps

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery

Libtayo&reg; (cemiplimab-rwlc) Data At ESMO 2018 Congress Provide New Insights In Six Tumor Types Under Investigation

Libtayo® (cemiplimab-rwlc) Data At ESMO 2018 Congress Provide New Insights In Six Tumor Types Under Investigation

- ESMO data demonstrate breadth of joint Regeneron and Sanofi immuno-oncology development program

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

FDA Approves Libtayo&reg; (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

FDA Approves Libtayo® (cemiplimab-rwlc) As First And Only Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.

FDA To Review Supplemental Biologics License Application For Praluent&reg; (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab) Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy

FDA To Review Supplemental Biologics License Application For Praluent&reg; (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

FDA To Review Supplemental Biologics License Application For Praluent® (alirocumab)Injection As Potential Treatment To Reduce Major Adverse Cardiovascular Events

Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy

TheStreet Quant Rating: C+ (Hold)